Overview

Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis

Status:
Suspended
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Study will evaluate the safety and potential benefit of talactoferrin (recombinant human lactoferrin) as an addition to the standard care for severe sepsis.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Agennix
Treatments:
Lactoferrin
Talactoferrin alfa